BioXcel Therapeutics
BTAI
BTAI
104 hedge funds and large institutions have $431M invested in BioXcel Therapeutics in 2020 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
70% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 20
49% more funds holding
Funds holding: 70 → 104 (+34)
0.65% more ownership
Funds ownership: 1.86% → 2.51% (+0.65%)
Holders
104
Holding in Top 10
3
Calls
$27.9M
Puts
$13.3M
Top Buyers
| 1 | +$45M | |
| 2 | +$26.1M | |
| 3 | +$16.6M | |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$15.9M |
| 5 |
BlackRock
New York
|
+$11.7M |
Top Sellers
| 1 | -$23.2M | |
| 2 | -$22.5M | |
| 3 | -$4.54M | |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$4.21M |
| 5 |
MAP
Moody Aldrich Partners
Marblehead,
Massachusetts
|
-$3.19M |